Study of a new drug combined with apatinib for advanced stomach and colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs for advanced stomach, gastroesophageal junction, or colorectal cancer. The drugs work in different ways to attack cancer cells and may help slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old, and able to care for yourself (ECOG status 0-1).
- Doctors must confirm the cancer is advanced and cannot be removed by surgery.
- You need to have at least one tumor that can be measured on imaging scans.
- Your blood counts and major organ functions (like liver and kidneys) must be within acceptable ranges.
- You must be willing to use effective birth control during and for 6 months after the study.
- You must not have certain other serious illnesses or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
This trial tests a combination of chemotherapy with two newer drugs (SHR-1701 and apatinib) as the first treatment for advanced pancreatic cancer. The goal is to see if this combination is safe and effective in slowing cancer growth.
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a new combination of three drugs for stomach cancer that has progressed after initial immunotherapy. It aims to see if this combo can shrink tumors or slow cancer growth, potentially offering a new option for patients like you.
This trial tests whether adding SHR-1701 (an immunotherapy) with or without apatinib (a targeted therapy) to standard chemotherapy before surgery can help treat gastric cancer. It is for people with stomach or gastroesophageal junction cancer that has spread to nearby lymph nodes but is still removable.
This trial tests a combination of two oral drugs, TAS-102 and apatinib, as a third-line treatment for advanced stomach cancer. It aims to see if this combination can help control the cancer when other treatments have not worked.
Hear when a new Advanced Gastric Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.